September 1, 2022PlateletsOpen Access

Clopidogrel versus ticagrelor in East Asian patients aged 75 years or older with acute coronary syndrome: observations from the GF-APT registry

View Full Paper

Ask AI

Bookmark

Why the study?

The efficacy and safety of ticagrelor in elderly East Asian populations remains debated due to concerns regarding an imbalance between ischemic and bleeding risks.

Does ticagrelor improve clinical outcomes compared to clopidogrel in East Asian patients aged ≥75 years with acute coronary syndrome?

Structured PICO

Does ticagrelor improve clinical outcomes compared to clopidogrel in East Asian patients aged ≥75 years with acute coronary syndrome?

Population

2,775 East Asian patients aged ≥75 years with acute coronary syndrome (ACS)

Intervention

Ticagrelor

Comparator

Clopidogrel

Outcome

Primary efficacy outcome (not explicitly defined in abstract)

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Ticagrelor should not yet be preferred in elderly East Asian ACS patients; leaves open optimal P2Y12 selection pending dedicated RCTs.

Cite This Study

Xi et al. (2022) studied this question.

synapsesocial.com/papers/6a84f539cf83b00b9b990abc https://doi.org/10.1080/09537104.2022.2118250

Topics

Dual antiplatelet therapy Percutaneous coronary intervention

View Full Paper

Ask AI

Bookmark

Clopidogrel versus ticagrelor in East Asian patients aged 75 years or older with acute coronary syndrome: observations from the GF-APT registry

Structured PICO

Discussion

Implication

Cite This Study

Topics

Clopidogrel versus ticagrelor in East Asian patients aged 75 years or older with acute coronary syndrome: observations from the GF-APT registry

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider